(by Phillip Altman | Brownstone Institute) – The US Department of Defense (US DoD) has had a dominant role in the response to the SARS-CoV-2 virus and in the development, and distribution of the Covid 19 vaccines, a fact hidden from the general public. In those processes many standard steps and procedures, otherwise required for pharmaceutical products, were omitted or circumvented.
Definition of these vaccines as “countermeasures” rather than therapeutic agents has permitted their expedited progression to emergency use authorisation and widespread rollouts. Many adverse consequences have been the outcome of this secret military response to a public health matter. Why are governments around the world, including Australia, planning to make further significant investments in this rushed vaccine technology driven by the US military?
Operation Warp Speed
With the US Food and Drug Administration’s Emergency Use Authorisation of the COVID-19 vaccines (FDA, 2020) and the Provisional Approval of the first COVID-19 vaccine in Australia (TGA, 2021), these agents were hailed as innovative life-saving responses by the pharmaceutical industry to a deadly global pandemic.
The development, testing and drug regulatory approval of these novel COVID-19 gene-based vaccines using messenger ribonucleic acid (mRNA) technology was said to have been done in less than one year, whereas development and approval of conventional vaccines normally takes about 10 years. (Seneff and Nigh, 2021). The public was told that this was assisted by financial support of vaccine companies by the US government under Operation Warp Speed.
The public was told that these COVID-19 gene-based vaccines were “safe and effective” (CDCa, 2022): that they would prevent infection and chances of serious illness and death from the virus, and would prevent transmission of the virus. We now know they do not prevent infection nor transmission and have not prevented a continuing high incidence of COVID-19. Furthermore they are associated with an unprecedented incidence of serious adverse events and deaths compared to any other drugs in the history of the pharmaceutical industry. (Turni and Lefringhausen 2022; Altman, 2022; CMN, 2022; Blaylock, 2022).
Based on the US CDC Vaccine Adverse Event Reporting System (VAERS), there were 1,476,227 adverse event reports associated with these “vaccines” (CDCb, 2022). through December 2, 2022, which include 32,621 reported deaths and 185,412 hospitalizations. Furthermore, a rise in unexplained deaths has been reported around the world coincident with their introduction. In Australia, up to August 2022 there were 18,671 excess deaths (17 percent) more than average, with most of these deaths not due to COVID-19 (ABS, 2022). We are probably facing the worst health disaster in history.
How did the pharmaceutical industry, our governments and our drug regulators get it so wrong? A plausible answer to this question has emerged within the last few weeks.
A National Security Operation
Contrary to popular belief that pharmaceutical companies drove the COVID vaccine development programs, the US FDA’s website (FDA, 2020) reveals that the United States Department of Defence (DoD) has been in full control of the Covid Vaccine development program since its beginning. The DoD has been responsible for development, manufacturing, clinical trials, quality assurance, distribution and administration, since that time (FDA, 2020; Rees and Latypova, 2022; KEI, 2022; Medical Defense Consortium, 2022; Rees, 2022). The major pharmaceutical companies have been involved as “Project Coordination Teams” effectively performing as subcontractors to the DoD. The Chief Operating Officer for the Warp Speed vaccine program is the US Department of Defence, and the Chief Science Advisor is the US Department of Health and Human Services (HHS).
The Nature of Gene-based Vaccines
The true nature of the COVID-19 ‘vaccines’ has been largely misrepresented by mainstream media, big pharmaceutical companies and governments and is poorly understood by the population at large. Referring to these products as “vaccines” led most people to consider them as relatively safe and well-researched and readily accept their widespread use. However, they are not really vaccines – they are serious gene-based interventions which have never been deployed widely in any population, especially never to healthy individuals including children, infants and pregnant women. In this sense they should be considered experimental.
COVID-19 ‘vaccines’ fall into a special class of therapeutic agents under the US FDA Office of Cellular, Tissue and Gene Therapies’ defined as “gene therapy products,” which involve “introducing a new or modified gene into the body to help treat a disease” (FDA, 2018). Heretofore, use of gene therapy products has been limited to the treatment of usually rare, serious and debilitating disease or genetic conditions. They have potential to cause permanent intergenerational genetic damage, cancer and interfere with reproductive capacity.
The FDA and other drug regulatory agencies have specific rules and guidelines to direct manufacturers in development and testing of such products, for both preclinical (FDA, 2013) and clinical (FDA, 2015) research. However, the FDA did not evaluate these COVID-19 “vaccines” according to these gene therapy guidelines.
Instead, there was a concerted effort to avoid referring to them as gene therapy products, based, in part, on the argument that the genetic material in the COVID-19 vaccines was not intended to be incorporated into an individual’s DNA, nor to modify gene expression. There was no prior short-term safety information and no long-term data on which to predict future effects. No similar therapeutic products have been previously approved anywhere in the world. Their widespread administration globally with no historical safety experience was an unprecedented risk in human health. Read Full Article >